Akzo Nobel Shareholders To Vote On Organon BioSciences IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
Dutch company’s planned separation of pharmaceuticals business from chemicals/coatings division is expected to be complete in two to three years.
You may also be interested in...
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.
Pfizer Ends Asenapine Collaboration With Organon
Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.